Skip to Content

Tekturna HCT Approval History

  • FDA approved: Yes (First approved January 18th, 2008)
  • Brand name: Tekturna HCT
  • Generic name: aliskiren and hydrochlorothiazide
  • Dosage form: Tablets
  • Company: Novartis Pharmaceuticals Corporation
  • Treatment for: High Blood Pressure

Tekturna HCT (aliskiren and hydrochlorothiazide) is a single-tablet combination therapy for the treatment of high blood pressure.

Development History and FDA Approval Process for Tekturna HCT

Jul 21, 2009Approval FDA Approves Tekturna HCT as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Jan 22, 2008Approval Tekturna HCT, a Single-Tablet Combination of Tekturna and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
May 21, 2007Single-Tablet Combination of Tekturna and Diuretic, an Important New Option for People With High Blood Pressure, Accepted for Review in U.S.

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.